LaFleur & Godfrey LLC Acquires 1,487 Shares of Bristol-Myers Squibb (NYSE:BMY)

LaFleur & Godfrey LLC grew its holdings in Bristol-Myers Squibb (NYSE:BMY) by 3.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 43,551 shares of the biopharmaceutical company’s stock after acquiring an additional 1,487 shares during the period. LaFleur & Godfrey LLC’s holdings in Bristol-Myers Squibb were worth $2,463,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Zhang Financial LLC grew its holdings in Bristol-Myers Squibb by 42.3% during the fourth quarter. Zhang Financial LLC now owns 5,826 shares of the biopharmaceutical company’s stock valued at $330,000 after purchasing an additional 1,732 shares during the period. MassMutual Private Wealth & Trust FSB lifted its position in shares of Bristol-Myers Squibb by 4.0% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 8,687 shares of the biopharmaceutical company’s stock valued at $491,000 after buying an additional 332 shares in the last quarter. Corundum Group Inc. grew its stake in shares of Bristol-Myers Squibb by 67.8% during the 4th quarter. Corundum Group Inc. now owns 43,534 shares of the biopharmaceutical company’s stock valued at $2,462,000 after acquiring an additional 17,596 shares during the period. UMB Bank n.a. increased its holdings in Bristol-Myers Squibb by 178.2% in the 4th quarter. UMB Bank n.a. now owns 205,457 shares of the biopharmaceutical company’s stock worth $11,621,000 after acquiring an additional 131,595 shares in the last quarter. Finally, M.E. Allison & CO. Inc. bought a new stake in Bristol-Myers Squibb during the 4th quarter worth approximately $419,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

BMY has been the topic of a number of analyst reports. TD Cowen lifted their target price on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Barclays boosted their price objective on Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a research report on Monday, October 7th. Leerink Partnrs upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 12th. Daiwa Capital Markets raised Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a report on Wednesday, November 13th. Finally, Jefferies Financial Group raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and increased their price objective for the company from $63.00 to $70.00 in a report on Monday, December 16th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $56.27.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,830 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The stock was purchased at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the purchase, the executive vice president now directly owns 62,109 shares in the company, valued at approximately $3,395,499.03. This trade represents a 3.04 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of the company’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $55.62, for a total transaction of $38,934.00. Following the transaction, the senior vice president now owns 11,760 shares of the company’s stock, valued at approximately $654,091.20. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.

Bristol-Myers Squibb Price Performance

Shares of Bristol-Myers Squibb stock opened at $56.35 on Monday. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $61.08. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83. The company has a 50 day moving average price of $57.53 and a 200 day moving average price of $52.00.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The firm had revenue of $11.89 billion during the quarter, compared to the consensus estimate of $11.26 billion. During the same quarter in the previous year, the company posted $2.00 earnings per share. The company’s revenue was up 8.4% compared to the same quarter last year. As a group, equities research analysts predict that Bristol-Myers Squibb will post 0.93 earnings per share for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be issued a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 4.40%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date is Friday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio is presently -69.08%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.